Opko Health (OPK) reported $607M in revenue for fiscal 2025, −14.9% year on year. That ranks #2096 by revenue among 2853 SEC filers and #200 in Healthcare. It posted a net loss of −$226M for the same year. Revenue has grown 7.1% a year on average since 2015 ($305M then). The fiscal 2025 balance sheet shows $1.9B in total assets, $364M in cash and $2.3M in long-term debt.
Scale corrected: the company's XBRL data reports net income (÷10³) without the scale factor (for example "4,801" for 4.8 billion). The figures are shown at the corrected scale; each links to the filing it comes from.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $607M | −14.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $206M | −5.8% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$117M | +$34.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$226M | −$172M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$179M | +$4.9M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $12.3M | −50.9% | FY20252025-12-31 |
| Total assetsAssets | $1.9B | −12.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.3B | −7.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $364M | −14.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $2.3M | −24.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $124M | −$54.8M | Open → |
| Q2 20262026-06-30 | $164M | −$8.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Opko Health, Inc.
- Ticker
- OPK
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000944809
Filings
- 10-QJul 27, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Axsome TherapeuticsAXSM | $638M | −$183M |
| TG TherapeuticsTGTX | $616M | $447M |
| Cadre HoldingsCDRE | $610M | $44.1M |
| Opko HealthOPK | $607M | −$226M |
| InsmedINSM | $606M | −$1.3B |
| Transmedics GroupTMDX | $605M | $190M |
| Ufp TechnologiesUFPT | $603M | $68.3M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Opko Health — Key figures |url=https://companiesranked.com/en/company/opko-health |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Opko Health — Key figures. CompaniesRanked. https://companiesranked.com/en/company/opko-healthBibTeX
@misc{companiesranked-en-company-opko-health-2026,
author = {{CompaniesRanked}},
title = {{Opko Health — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/opko-health}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-076596 · February 26, 2026
{{cite web |title=Opko Health — Key figures — 10-K (0001193125-26-076596) |url=https://www.sec.gov/Archives/edgar/data/944809/000119312526076596/opk-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.